Market Place
Sourcing Support
Clearpoint Neuro Unveils FDA-Cleared Velocity Alpha(R) MR Drill
22 Apr 2026 //
PHARMIWEB
ClearPoint Neuro Secures Health Canada Nod for Navigation System
20 Apr 2026 //
ACCESSWIRE
ClearPoint Neuro Releases 2025 Q4 And Full-Year Financial Results
17 Mar 2026 //
PHARMIWEB
Clearpoint Neuro To Unveil Q4 And Full Year 2025 Results
06 Mar 2026 //
PHARMIWEB
ClearPoint Announces Preliminary Unaudited Q4 & Year 2025 Revenue
12 Jan 2026 //
PHARMIWEB
Clearpoint Neuro Completes Acquisition Of IRRAS
20 Nov 2025 //
PHARMIWEB
Clearpoint Neuro Reports Third Quarter 2025 Results
06 Nov 2025 //
PHARMIWEB
Clearpoint Neuro Announces Agreement To Acquire IRRAS
06 Nov 2025 //
PHARMIWEB
Clearpoint Neuro To Join Global Healthcare Conferences In Q4 2025
05 Nov 2025 //
PHARMIWEB
Clearpoint Neuro Reveals Positive Brain Tumor Laser Therapy
07 Oct 2025 //
ACCESSWIRE
ClearPoint Neuro Expands Therapy Delivery Clearance To 34 Nations
06 Oct 2025 //
ACCESSWIRE
Clearpoint Neuro Unveils Robotic Neuro-Navigation System
01 Oct 2025 //
ACCESSWIRE
Clearpoint Neuro Names Dr. Paul Larson Chief Medical Officer
25 Sep 2025 //
ACCESSWIRE
ClearPoint Neuro`s Q2 2025 Results Released
12 Aug 2025 //
ACCESSWIRE
ClearPoint Neuro Reports Milestones in Biologics, Drug Delivery
04 Aug 2025 //
ACCESSWIRE
ClearPoint Neuro Reports First Quarter 2025 Results
13 May 2025 //
ACCESSWIRE
ClearPoint Neuro gets up to $110M investment from Oberland Capital
12 May 2025 //
ACCESSWIRE
ClearPoint Submits FDA Filing to Expand Prism Label for 1.5T MRI
28 Apr 2025 //
ACCESSWIRE
ClearPoint Neuro to Announce Q1 2025 Results on May 13
25 Apr 2025 //
ACCESSWIRE
ClearPoint Neuro Releases ClearPoint Navigation Software 3.0
24 Apr 2025 //
ACCESSWIRE
ClearPoint Neuro To Announce Q3 2024 Results On November 7
17 Oct 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Announces Early Repayment of $10 Million Note
26 Aug 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Reports Second Quarter 2024 Results
07 Aug 2024 //
GLOBENEWSWIRE
ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024
17 Jul 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Celebrates Partner Aspen Neuroscience Using ClearPoint® System
20 Jun 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Announces Full Market Release Of Therapy Systems
01 Jun 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Reports First Quarter 2024 Results
06 May 2024 //
GLOBENEWSWIRE
ClearPoint At ASGCT With Novel Gene Therapy Research
02 May 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Announces FDA Clearance of Prism Bone Anchor Accessory
29 Apr 2024 //
GLOBENEWSWIRE
ClearPoint Initiates SmartFrame OR™ System Limited Release
24 Apr 2024 //
GLOBENEWSWIRE
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
23 Apr 2024 //
GLOBENEWSWIRE
ClearPoint Congratulates its Partner PTC of BLA Sub to FDA for Upstaza
19 Mar 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
12 Mar 2024 //
GLOBENEWSWIRE
Journal of Neurosurgery Publication Shows Advantage of ClearPoint Therapy System
11 Mar 2024 //
GLOBENEWSWIRE
ClearPoint to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
01 Mar 2024 //
GLOBENEWSWIRE
ClearPoint Announces Pricing of Offering of 2,307,694 Shares of Common Stock
29 Feb 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
28 Feb 2024 //
GLOBENEWSWIRE
ClearPoint Announces First-in-Human Cases Performed with 2.2 Software Version
21 Feb 2024 //
GLOBENEWSWIRE
ClearPoint Announces First Procedure Using the ClearPoint Laser Therapy System
24 Jan 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Announces First EU MDR Certification Success
22 Jan 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Announces FDA Clearance for SmartFrame OR„¢ Stereotactic System
16 Jan 2024 //
GLOBENEWSWIRE
ClearPoint Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results
08 Jan 2024 //
GLOBENEWSWIRE
ClearPoint Neuro Reports Third Quarter 2023 Results
09 Nov 2023 //
GLOBENEWSWIRE
ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023
26 Oct 2023 //
GLOBENEWSWIRE
ClearPoint Neuro Reports Second Quarter 2023 Results
08 Aug 2023 //
GLOBENEWSWIRE
ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023
25 Jul 2023 //
GLOBENEWSWIRE
ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
24 May 2023 //
GLOBENEWSWIRE
ClearPoint Neuro to Present at the B. Riley Securities 2023 Conference
18 May 2023 //
GLOBENEWSWIRE
ClearPoint Neuro Reports First Quarter 2023 Results
11 May 2023 //
GLOBENEWSWIRE
ClearPoint Neuro to Present Investigational Research and Showcase
10 May 2023 //
GLOBENEWSWIRE
ClearPoint Neuro to Showcase Two Novel Innovations at AANS 2023
20 Apr 2023 //
GLOBENEWSWIRE
ClearPoint Neuro Announces Agreement with NE Scientific to Gene Therapy
18 Apr 2023 //
GLOBENEWSWIRE
ClearPoint Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil
13 Apr 2023 //
GLOBENEWSWIRE
ClearPoint Extends Software License and Research Agreement with Philips
11 Apr 2023 //
GLOBENEWSWIRE
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF
28 Mar 2023 //
GLOBENEWSWIRE
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results
01 Mar 2023 //
GLOBENEWSWIRE
ClearPoint to Announce Q4 and Full Year 2022 Revenue Results March 1, 2023
15 Feb 2023 //
GLOBENEWSWIRE
ClearPoint Neuro Reports Q4 and Full Year 2022 Preliminary Revenue Results
11 Jan 2023 //
GLOBENEWSWIRE
ClearPoint Neuro First Patient Enrolled in Glioblastoma Trial ClearPoint Prism™
12 Dec 2022 //
GLOBENEWSWIRE
ClearPoint Neuro to Announce Third Quarter 2022 Results November 8, 2022
26 Oct 2022 //
GLOBENEWSWIRE
